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Abstract
Purpose Radial scar’s stellate appearance may mimic carcinoma mammographically and histologically. Management of 
radial scar (RS) found on breast core needle biopsies (CNB) ranges from excision to clinical observation due to the variation 
in reported upgrades to malignancy at surgical excision. We examined the upgrade rate in patients with RS detected on CNB 
at our institution and reviewed the current literature.
Methods A retrospective study was conducted of all cases with RS diagnosed on CNB between December 2006 and March 
2017 at our institution. Inclusion criteria were patients with “pure” RS and RS associated with high-risk lesions (HRL). 
Upgrade was defined as invasive or non-invasive cancer in the excisional biopsy.
Results 157 cases were identified with RS on CNB, and 122 cases met inclusion criteria. Of these 122 cases, 91 (75%) had 
pure RS on CNB while 31 (25%) had associated atypia or HRL. 81 (66%) of patients proceeded to excisional biopsy and 
41 (34%) did not. Two patients (1.6% of total) were found to have a low-grade invasive ductal carcinoma (0.6 and 0.8 cm) 
upon surgical excision. None of the remaining 120 patients developed an ipsilateral breast cancer with a mean of 32.3-month 
follow-up.
Conclusions We found a very low upgrade rate to breast cancer when RS was found on CNB with or without associated 
HRL. Our results are consistent with other reported series. Our data do not support surgical excision for RS but rather close 
clinical follow-up for patients with RS on CNB.
Keywords Breast cancer · Radial scar · Core needle biopsy
Introduction
Radial scars (RS) are entities which are described mam-
mographically and pathologically. They are benign breast 
lesions that are commonly detected by pathologists [1]. The 
risk of subsequent breast cancer associated with RS found 
on pathology with and without atypia ranges from 1.1–3.0 to 
2.8–6.7% respectively [2]. Patients with RS in benign breast 
biopsies were found to have twice as great risk of subsequent 
breast cancer [1, 3].
Radiographically, RS are characterized by an area of 
architectural distortion with a central radiolucency and the 
presence of radiating spicules. RS, detected on breast patho-
logical specimens, are benign lesions and are part of the 
sclerosing adenosis spectrum. Histologically, RS are char-
acterized by a central fibroelastic core containing entrapped 
glandular elements and ducts that radiate outward giving the 
lesion a characteristic stellate appearance. Histologic and 
radiographic RS do not have an exact correspondence [4–6] 
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and the majority of pathological RS are found incidentally 
at biopsy for unrelated mammography findings. Because of 
the reported association of RS with surrounding proliferative 
disease and malignancy, excisional biopsy of RS detected on 
core needle biopsy (CNB) has been advocated [7–9].
Several histological diagnoses found at image-guided 
CNB of breast lesions have been shown to be associated with 
a sampling error rate that is high enough to warrant surgi-
cal excision. RS found on CNB from image-guided biopsies 
may be a microscopic incidental finding, may account for 
the imaging findings, or may be a high-risk lesion warrant-
ing surgical excision. Several retrospective reviews of sur-
gical specimens obtained after RS diagnosis on CNB have 
reported an increased incidence of associated proliferative 
disease, malignancy, or both [7, 9–15]. Some studies have 
reported malignancy rates associated with RS with surgical 
excision as high as 29–30% [9, 16, 17]. Based on the asso-
ciation of RS with other proliferative or malignant processes 
or the possibility of sampling error, surgical excision has 
become the standard of care to avoid missing a low-grade 
cancer or upgrading to a high-risk lesion.
Given the improvement in imaging, biopsy devices, and 
pathological examination, we examined the outcome of 
patients with RS detected on CNB at our institution as well 
as reviewed the current literature.
Methods
This retrospective study was reviewed and approved by the 
Institutional Review Board of Washington University School 
of Medicine. The Barnes-Jewish Hospital pathology data-
base was searched for the terms “RS” and “RS core” from 
December 2006 to March 2017. Inclusion criteria included 
patients with “pure” RS and RS associated with high-risk 
lesions (HRL). Both imaging-targeted lesions and incidental 
pathologic findings of RS were included. Exclusion criteria 
were RS associated with malignancy at percutaneous biopsy, 
patients with simultaneous or previous ipsilateral breast can-
cer diagnosis within 6 months prior to CNB, patients who 
were lost to follow up as defined by last follow-up date cor-
responding to the date of the CNB, and patients who were 
never physically seen at our medical center, though their 
pathology was reviewed at our institution. Follow-up was 
defined as the time interval from the CNB to the date of the 
last recorded visit to our institution.
All mammograms were interpreted and biopsies recom-
mended by a core of five radiologists who are dedicated 
fellowship trained mammographers. All pathology results 
were interpreted by dedicated breast pathologists. Each 
CNB was recorded for its modality [stereotactic, ultra-
sound (US), or MRI-guided], mammographic finding, and 
excisional pathology when performed. Ipsilateral atypia or 
carcinoma in the same core biopsy was also recorded. High-
risk lesions (HRL) included atypical ductal hyperplasia 
(ADH), lobular carcinoma in situ (LCIS), atypical lobular 
hyperplasia (ALH), and papilloma. In cases where there was 
more than one HRL in the biopsy, the higher ranked HRL 
was recorded. For our study, an upgrade from the CNB was 
defined as upgrade to an invasive or non-invasive breast can-
cer on the excisional pathology report. Benign lesions were 
defined as any lesion that did not require further clinical 
treatment.
Statistical method
Tests for statistical significance of the association between 
demographic/clinicopathologic factors and pathologic 
upgrade were performed using the Chi square (χ2) test. Sta-
tistical significance was defined to be P < 0.05.
Results
RS was identified on 157 image-guided CNB. 35 cases 
were excluded from this study due to simultaneous ipsilat-
eral breast cancer, lost to follow up, or never seen at our 
medical center (Supplemental Table 1). Of the remaining 
122 patients, approximately one-third of the women were 
between the ages of 50 and 69. Approximately 80% were 
Caucasian and 20% minority, reflective of the population 
served by the medical center. The most common mammo-
graphic findings for biopsy recommendation were archi-
tectural distortions (27%), mass (22%), and calcifications 
(19%). Mammographic mass diameter measured from the 
mammographic or US views ranged from 0.3 to 3.5 cm 
(mean 0.9  cm). The most common types of diagnostic 
biopsies performed were stereotactic core vacuum-assisted 
biopsy (VAB) with 9-gauge needles (67%), followed by US-
guided biopsy with 14-gauge needles (24%) and MRI-guided 
biopsy with 9-gauge needles (9%) (Table 1).
81 (66%) of 122 patients underwent a surgical excision 
of the RS area and 41 (34%) did not. Seven of the patients 
(17%) who did not undergo an excision were diagnosed with 
a concurrent contralateral breast cancer and the RS was diag-
nosed during their work-up. The mean age of those undergo-
ing excision was 64 versus 58 for those who did have further 
surgery and this was significant (P = 0.02). Otherwise, there 
was no significant difference in race, mammographic indica-
tion for core biopsy, type of core biopsy, and biopsy needle 
gauge between those patients who had an excision versus 
those who did not. There were a slightly higher percentage 
of African-American women who did not undergo surgical 
excision compared to African-American women who under-
went surgery (19 vs. 5% respectively) (Table 1).
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RS with atypia on core biopsy
Of the 122 core pathologies reviewed, 91 (75%) were 
not associated with atypia and 31 (25%) were associated 
with atypia, including ADH, ALH/LCIS, and papilloma 
(Table 2). Of the 31 patients with RS and atypia on image-
guided CNB, 26 (84%) of the patients had an excisional 
biopsy and none of these patients were diagnosed with a 
breast cancer on the excisional biopsy (Fig. 1). None of the 
five patients who did not have an excisional biopsy (all with 
RS/papilloma on CNB) were later diagnosed with an ipsi-
lateral breast cancer with a mean follow-up of 75.0 months 
Table 1  Demographics and clinicopathologic features of 122 patients with RS on breast core biopsy
*Statistically significant P < 0.05
Characteristic Patients who underwent surgical 
excision, n = 81 (%)
Patients who did not undergo surgical 
excision, n = 41 (%)
P value
Age—n (%) 0.02*
 < 39 4 (5) 0 (0)
 40–49 15 (19) 6 (15)
 50–59 30 (37) 7 (17)
 60–69 22 (27) 13 (32)
 70–79 8 (10) 12 (29)
 > 80 2 (2) 3 (7)
Age—mean (SD) 58 (10) 64 (12)
Race/ethnicity—n (%) 0.09
 White 71 (88) 32 (78)
 Hispanic 0 (0) 0 (0)
 Asian 2 (2) 1 (2)
 African-American 4 (5) 8 (20)
 Other 2 (2) 0 (0)
 Unknown 2 (2) 0 (0)
Indication for core biopsy—n (%) 0.10
 Architectural distortions 26 (32) 7 (17)
 Architectural distortions + calcifications 10 (12) 3 (7)
 Architectural distortions + mass 8 (10) 1 (2)
 Architectural distortions + focal asymmetry 0 (0) 1 (2)
 Mass 17 (21) 10 (24)
 Mass + calcifications 0 (0) 2 (5)
 Asymmetrical density 1 (1) 0 (0)
 Focal asymmetry 4 (5) 4 (10)
 Focal asymmetry + mass 1 (1) 0 (0)
 Calcifications/microcalcifications 12 (15) 12 (29)
 Non-mass like enhancement 2 (2) 1 (2)
Type of core biopsy—n (%) 0.47
 Stereotactic 52 (64) 30 (73)
 Ultrasound 22 (27) 7 (17)
 MRI-guided 7 (9) 4 (10)
Biopsy needle gauge (G)—n (%) 0.84
 9 G-vacuum assisted 74 (91) 37 (90)
 14 G-spring assisted 7 (9) 4 (10)
Table 2  Core needle biopsy pathology (n = 122)
Core biopsy results n (%)
“Pure” radial scar 91 (75)
Radial scar with ADH 9 (7)
Radial scar with lobular neoplasia 8 (7)
Radial scar with papilloma 14 (11)
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(range 0.4–111.6 months) nor were any of the patients 
who had an excisional biopsy diagnosed with an ipsilateral 
breast cancer with a mean follow-up of 23.4 months (range 
0.5–94.0 months) (Table 3).
Pure radical scar
Of those 91 patients with RS only on core biopsy, 55 (60%) 
underwent an excisional biopsy and 36 (40%) did not 
(Fig. 1). Of those 36 patients who did not undergo an exci-
sional biopsy, none of the patients developed an ipsilateral 
breast cancer with a mean follow-up of 42.9 months (range 
0.1–101.2 months). Of the 55 patients without atypia who 
did undergo surgical excision, 53 (96%) of the pathologies 
were benign and 2 cases yielded small invasive cancers. 
Both cancers were invasive ductal carcinoma (IDC), grade 
1, estrogen receptor-positive/Her2-negative and were 0.6 and 
0.8 cm, respectively (Table 4).
Contralateral breast cancer
In our study, 18 patients had concurrent contralateral breast 
cancer. Of these patients, 11 had pure RS found on CNB, 
while 7 had associated atypia on CNB. Patients with associ-
ated atypia on CNB all underwent surgical excision and all 
of the pathologies were benign. Of the patients with pure RS 
found on CNB, 4 underwent excision with resultant benign 
pathology, while 7 underwent imaging follow-up (mean 
49.3 months, range 0.7–101.2 months). The mean follow-
up for this group was 39.9 months, and none of the patients 
developed an ipsilateral breast cancer. All received appropri-
ate treatment for their contralateral breast cancer.
RS Core Biopsies (122)
No Atypia on Core (91) Atypia on Core (31)







Fig. 1  Outcome of patients diagnosed with RS on CNB (number). Number of cases with contralateral breast cancer: a7 cases, b4 cases
Table 3  Surgical pathology of radial scars (n = 81)
Biopsy pathology n (%) Surgical pathology
“Pure” radial scar 55 (68) 2 IDC
Radial scar with ADH 9 (11) All benign
Radial scar with lobular neoplasia 8 (10) All benign
Radial scar with papilloma 9 (11) All benign
Table 4  Cancer upgrade cases after surgical excision




59 Mammogram Architectural distor-
tion, mass (8 mm)
RS US-guided spring assisted 14 G IDC, grade 1, 6 mm ER+/
PR+/
Her2−
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Literature review
We reviewed 16 studies (including our data) published 
from 2014 to 2018 with chart reviews from 1994 to 2017 
(Table 5). For each study, the number of excisions performed 
after pure RS was found on initial CNB, and the number 
of upgrades to carcinoma, both invasive and non-invasive, 
and the type of carcinoma [DCIS or Invasive Breast Cancer 
(IBC) which includes IDC and invasive lobular carcinoma 
(ILC)] were recorded. An overall upgrade rate among the 
studies was calculated. From our literature review, there 
were a total of 37 out of 1085 cases of upgrades to carci-
noma yielding an overall upgrade rate of 3.4%, which is 
consistent with our institutional study.
Of the 15 other studies, four studies: Nassar et al. [18], 
Mooney et al. [3], Rageth et al. [2], and Ferreira et al. [19] 
yielded comparatively high upgrade rates (10.5, 16.0, 10.9, 
13.5%, respectively, average upgrade rate 12.6%, 25 of 
198 total patients) to malignancy compared to the other 
11 studies (average upgrade 1.4%, 12 of 887 patients). 
The exclusion criteria for first three studies were similar 
in that patients with any atypia observed with RS on CNB 
were excluded. Nassar et al. also excluded cases in which 
the pathological diagnosis on the CNB was RS (≤ 1.0 cm) 
or Complex Sclerosing Lesions (CSL) (> 1.0 cm) associ-
ated with atypical epithelial hyperplasia, lobular neopla-
sia, DCIS, and malignancy [18]. Mooney et al. excluded 
RS associated with any type of epithelial atypia and cases 
with known synchronous ipsilateral breast cancer [3]. Fer-
reria et al. excluded patients with a simultaneous breast 
malignancy (invasive or in situ breast cancer) and also 
patients with a follow-up interval less than 12 months if 
surgery was not performed after an image-guided CNB 
[19]. Rageth et al. did not specifically list exclusion crite-
ria in their publication [2]. Whereas the exclusion criteria 
of the remaining 11 studies were all patients with con-
current ipsilateral breast cancer, coexisting atypia present 
with RS in core specimen, excision at an outside insti-
tution, lost to follow up after benign pathology results, 
and/or radiology–pathology discordance [20–30]. Thus, 
variability in exclusion criteria may account for the higher 
upgrade rates in some studies compared with others.
Discussion
It has been recommended that patients with RS detected 
on image-guided CNB undergo surgical excision due to 
the high upgrade rate observed in surgical specimens. In 
our institutional series, we observed a low upgrade rate 
of 3.6% for all patients who had a surgical excision after 
CNB. Consistent with our finding, review of literature 
published between years 2014 and 2018, yielded an overall 
upgrade rate of 3.4%. Moreover, with a mean follow-up of 
32.3 months, none of the other 120 patients in our series 
developed IBC or DCIS in the area of the RS biopsy, with 
or without excision.
A distinction needs to be made between RS detected 
mammographically versus that detected histopathologi-
cally. RS detected mammographically have been reported 
to be associated with early breast cancer, DCIS, and ADH 
Table 5  Literature review Year Author Upgrade 
rate (%)
Excision (n) Upgrade (n) DCIS (n) IBC (n)
2014 Miller et al. [24] 2.0 102 2 1 1
2015 Matrai et al. [25] 0.0 77 0 0 0
2015 Conlon et al. [21] 0.0 47 0 0 0
2015 Nassar et al. [18] 10.5 38 4 2 2
2016 Leong et al. [20] 0.6 161 1 1 0
2016 Donaldson et al. [26] 0.0 37 0 0 0
2016 Mooney et al. [3] 16.0 25 4 3 1
2016 Kalife et al. [27] 2.4 41 1 1 0
2016 Park et al. [28] 0.0 10 0 0 0
2016 Li et al. [22] 0.9 220 2 1 1
2016 Hou et al. [29] 0.0 40 0 0 0
2016 Kim et al. [23] 1.6 63 1 1 0
2016 Rageth et al. [2] 10.9 46 5 4 1
2017 Nakhlis et al. [30] 8.8 34 3 2 1
2017 Ferreira et al. [19] 13.5 89 12 7 5
2018 Chou et al. 3.6 55 2 0 2
Total 3.4 1085 37 23 14
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in up to half of women and thus should be sampled by 
image-guided biopsy [4]. This is in contrast to RS detected 
on core biopsies for abnormal mammographic findings.
RS found histopathologically on CNB have been asso-
ciated with multiple mammographic entities including 
masses, architectural distortion, calcifications, asym-
metries, and may or may not correspond to RS detected 
mammographically [2, 8]. Our data and data reported in 
the literature indicate that there is no single radiographic 
or mammographic finding associated with upgrade of 
RS found on CNB to a cancer or which identifies those 
RS which need to be excised versus those which can be 
safely monitored [31, 32]. For example, in our series, the 
mammographic findings which triggered the initial CNB 
in the two cases upgraded to cancer were a mass and an 
architectural distortion. In other reported series, upgrade 
to cancers was associated with architectural distortions, 
larger masses (≥ 1 cm), calcifications, and older age [3, 
22, 23]. Thus, the management of RS detected on CNB 
has ranged from surgical excision [33] or mammographic 
surveillance [4].
Part of the current RS management dilemma is the high 
variability of upgrade rates of pure RS among different 
institutional studies. In our review of 16 studies, including 
our data, published between 2014 and 2018, we calculated 
an overall upgrade rate to cancer of approximately 3.4% in 
patients diagnosed with RS on image-guided CNB with a 
range of 0–16.0%. While no single factor could account for 
the wide range in upgrade rate in the studies, several fac-
tors, such as year of the biopsy, biopsy device, and patient 
population, may affect the variability upgrade rate in the 
reported studies.
We found that more contemporary studies, with data 
from 2000 to 2017, reported very low upgrade rates. 
Kim et al. reported an upgrade rate on excision of 1.6% 
(1 out of 63 patients) [23]. Similar to our study, 25% of 
their patients did not undergo surgical excision and with 
a median follow-up of 26 months; none of the patients 
developed cancer. Leong et al. found an upgrade rate < 1% 
in 161 patients with pure RS [20].
The type of biopsy device on upgrade rate has been 
examined to determine whether larger core biopsy gauge 
or VAB led to an improved false-negative rate for cancer 
detection when radial scar is detected on CNB. If a VAB 
showed RS on histology, some believed surveillance to be 
sufficient [2]. Three studies reported no upgrade to malig-
nancy if VAB or needle greater than 11 g is used [34–36]. 
These three studies had a combined patient population of 
422, which represents about 22% of the patients in the 
studies we reviewed; thus, it is can be reasonably assumed 
that RS detected on CNB using large core gauge or VAB 
can be safely managed conservatively.
High variability in upgrade rates may be due to differ-
ences in inclusion criteria for each study, which can lead 
to case selection bias. For example, in studies reported by 
Hou et al. [29] and Li et al. [22], all patients with a history 
or family history of breast cancer or atypical proliferative 
lesions defined as flat epithelial atypia, atypical ductal 
hyperplasia, and lobular neoplasia were excluded. As a 
result, Hou et al. [29] and Li et al. [22] observed upgrade 
rates of 0.0 and 0.9%, respectively.
Variability can also be attributed to the method some 
studies chose to characterize RS. Matrai et al. [25] limited 
the study population to those RS with that were 0.5 cm or 
smaller. However, studies have included patients with RS 
ranging from 0.1 to 5 cm [25, 32, 35, 37].
Upgrade from RS to cancers may be incidental find-
ings as has previously been discussed [20–22] and is 
likely the case with the two patients in our series. Most 
cancers detected on surgical excision for RS on CNB are 
low grade and prognostically favorable [16, 31, 38, 39]. 
In the literature review, 2.1% of patients had DCIS after 
excision for RS on CNB and 1.3% had IBC. Thus, these 
indolent cancers may have become apparent with close 
clinical follow-up and later detection would likely have 
little effect on overall patient outcome.
In our institutional study, none (0/26) of the RS with 
atypia on CNB were upgraded to malignancy upon surgi-
cal excision. This is in contrast to the higher number of 
upgrades to malignancy upon surgical excision with initial 
diagnosis of RS with associated atypia on CNB seen in 
other studies [3, 4, 20, 26, 35]. In two studies of RS and 
HRL on CNB, Leong et al. [20] found 6 of 54 (11%) cases 
of surgical pathology upgrades and Donaldson et al. [26] 
found 7 of 21 (33%) cases of upgrades to malignancy. Our 
low rate of upgrade in RS with HRL on CNB could be due 
to the low patient number, improved imaging, and biopsy 
devices.
Several studies published between 2007 and 2012 sug-
gested surgical excision of pure RS on CNB, due to the asso-
ciation with malignancy [32, 37] and false-negative biopsy 
in RS [33]. Nizri et al. examined the practice management 
of RS detected on image-guided biopsies [40] and found 
that 40% of breast surgeons recommended selective excision 
based on imaging and pathological correlation, size of the 
lesion, and the presence of atypia on the pathology and 57% 
of the respondents recommended routine excision.
Considering the advancements in breast imaging, pathol-
ogy, and multidisciplinary approaches to current RS man-
agement, along with our findings in this study, we believe 
that surgical excision is not necessary for RS without associ-
ated atypia on core needle biopsies. Instead follow-up imag-
ing, a less invasive approach, appears appropriate given the 
low upgrade rates to malignancy and the low-grade cancers 
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detected. This would save 97 patients a surgical procedure to 
detect 3 low-grade cancers, 2 of which are likely to be DCIS.
There are limitations to our study including single institu-
tion, retrospective patient population, and high volume prac-
tice with dedicated mammographers and breast pathologists, 
which may not be available at every institution. We were also 
unable to reliably obtain information on related family his-
tory of cancer. Additionally, as with any retrospective study, 
we are subject to impose our biases on our sample popula-
tion and are also limited to the cases seen at our institution.
Conclusion
We have found a low upgrade rate to cancer in RS and RS 
with HRL detected on image-guided CNB. Our results are 
consistent with other large institutional studies. Given the 
low upgrade rate to malignancy, we propose that upon find-
ing small, incidental RS on CNB, subsequent surgical exci-
sion is not necessary unless there are other reasons for exci-
sion such as the presence of HRL or discordance with the 
mammographic findings. Instead, close clinical follow-up or 
routine imaging, a less invasive approach, is recommended.
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